A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease

NCT01559363 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Polycystic Kidney, Autosomal Dominant

Interventions

DRUG: Tesevatinib

Sponsor

Kadmon, a Sanofi Company